Coherus Oncology (CHRS) Other Non-Current Liabilities (2013 - 2026)

Coherus Oncology has reported Other Non-Current Liabilities for 14 years, with the latest figure at $17.0 million in Q1 2026.

• Quarterly Other Non-Current Liabilities fell 45.78% year-over-year to $17.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.0 million (down 45.78% YoY) and the FY2025 annual result came in at $1.8 million, down 93.81% from the prior year.
• Other Non-Current Liabilities grew to $17.0 million in Q1 2026 per CHRS's latest filing, from $1.8 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $31.3 million in Q1 2025 and troughed at $102000.0 in Q1 2022.
• A 5-year average of $8.5 million and a median of $1.8 million in 2025 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities soared 27053.92% in 2024, then plunged 93.81% in 2025.
• Over 5 years, Other Non-Current Liabilities stood at $3.5 million in 2022, then surged by 262.3% to $12.6 million in 2023, then surged by 133.49% to $29.3 million in 2024, then sank by 93.81% to $1.8 million in 2025, then jumped by 834.77% to $17.0 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $17.0 million, $1.8 million, and $102000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.